#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The increasing resistances of pathogenic bacteria are one great problem for worldwide health policy , because it means a threat of humanity .
3-1	17-20	The	abstract[3]	new[3]	coref	3-8[5_3]
3-2	21-31	increasing	abstract[3]	new[3]	_	_
3-3	32-43	resistances	abstract[3]	new[3]	_	_
3-4	44-46	of	abstract[3]	new[3]	_	_
3-5	47-57	pathogenic	abstract[3]|animal[4]	new[3]|new[4]	coref	4-1[11_4]
3-6	58-66	bacteria	abstract[3]|animal[4]	new[3]|new[4]	_	_
3-7	67-70	are	_	_	_	_
3-8	71-74	one	abstract[5]	giv[5]	coref	10-18[47_5]
3-9	75-80	great	abstract[5]	giv[5]	_	_
3-10	81-88	problem	abstract[5]	giv[5]	_	_
3-11	89-92	for	abstract[5]	giv[5]	_	_
3-12	93-102	worldwide	abstract[5]|abstract[7]	giv[5]|new[7]	ana	3-17[0_7]
3-13	103-109	health	abstract[5]|abstract|abstract[7]	giv[5]|new|new[7]	_	_
3-14	110-116	policy	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
3-15	117-118	,	_	_	_	_
3-16	119-126	because	_	_	_	_
3-17	127-129	it	abstract	giv	_	_
3-18	130-135	means	_	_	_	_
3-19	136-137	a	abstract[9]	new[9]	_	_
3-20	138-144	threat	abstract[9]	new[9]	_	_
3-21	145-147	of	abstract[9]	new[9]	_	_
3-22	148-156	humanity	abstract[9]|person	new[9]|new	_	_
3-23	157-158	.	_	_	_	_

#Text=Pathogenic bacteria can be found in human surroundings , and drinking water may be contaminated with bacteria in developing countries .
4-1	159-169	Pathogenic	animal[11]	giv[11]	coref	4-17[0_11]
4-2	170-178	bacteria	animal[11]	giv[11]	_	_
4-3	179-182	can	_	_	_	_
4-4	183-185	be	_	_	_	_
4-5	186-191	found	_	_	_	_
4-6	192-194	in	_	_	_	_
4-7	195-200	human	place[12]	new[12]	_	_
4-8	201-213	surroundings	place[12]	new[12]	_	_
4-9	214-215	,	_	_	_	_
4-10	216-219	and	_	_	_	_
4-11	220-228	drinking	substance[13]	new[13]	_	_
4-12	229-234	water	substance[13]	new[13]	_	_
4-13	235-238	may	_	_	_	_
4-14	239-241	be	_	_	_	_
4-15	242-254	contaminated	_	_	_	_
4-16	255-259	with	_	_	_	_
4-17	260-268	bacteria	animal	giv	coref	5-14[19_0]
4-18	269-271	in	_	_	_	_
4-19	272-282	developing	_	_	_	_
4-20	283-292	countries	place	new	coref	13-14[60_0]
4-21	293-294	.	_	_	_	_

#Text=In the last century sufficient antibacterials were available to effectively treat infections with those various bacteria .
5-1	295-297	In	_	_	_	_
5-2	298-301	the	time[16]	new[16]	_	_
5-3	302-306	last	time[16]	new[16]	_	_
5-4	307-314	century	time[16]	new[16]	_	_
5-5	315-325	sufficient	abstract[17]	new[17]	coref	6-2[20_17]
5-6	326-340	antibacterials	abstract[17]	new[17]	_	_
5-7	341-345	were	_	_	_	_
5-8	346-355	available	_	_	_	_
5-9	356-358	to	_	_	_	_
5-10	359-370	effectively	_	_	_	_
5-11	371-376	treat	_	_	_	_
5-12	377-387	infections	abstract	new	coref	8-5[33_0]
5-13	388-392	with	_	_	_	_
5-14	393-398	those	animal[19]	giv[19]	coref	7-20[31_19]
5-15	399-406	various	animal[19]	giv[19]	_	_
5-16	407-415	bacteria	animal[19]	giv[19]	_	_
5-17	416-417	.	_	_	_	_

#Text=Beside the standard antibacterials like penicillin , reserve antibiotics have been discovered from natural sources and were resynthesized by industrial companies .
6-1	418-424	Beside	_	_	_	_
6-2	425-428	the	abstract[20]	giv[20]	coref	24-1[121_20]
6-3	429-437	standard	abstract[20]	giv[20]	_	_
6-4	438-452	antibacterials	abstract[20]	giv[20]	_	_
6-5	453-457	like	abstract[20]	giv[20]	_	_
6-6	458-468	penicillin	abstract[20]|substance	giv[20]|new	_	_
6-7	469-470	,	_	_	_	_
6-8	471-478	reserve	substance[22]	new[22]	coref	7-8[27_22]
6-9	479-490	antibiotics	substance[22]	new[22]	_	_
6-10	491-495	have	_	_	_	_
6-11	496-500	been	_	_	_	_
6-12	501-511	discovered	_	_	_	_
6-13	512-516	from	_	_	_	_
6-14	517-524	natural	object[23]	new[23]	coref	21-1[106_23]
6-15	525-532	sources	object[23]	new[23]	_	_
6-16	533-536	and	_	_	_	_
6-17	537-541	were	_	_	_	_
6-18	542-555	resynthesized	_	_	_	_
6-19	556-558	by	_	_	_	_
6-20	559-569	industrial	organization[24]	new[24]	coref	15-15[74_24]
6-21	570-579	companies	organization[24]	new[24]	_	_
6-22	580-581	.	_	_	_	_

#Text=However , an abuse and overuse of those antibiotics is one of the reasons for the present crisis with resistant bacteria .
7-1	582-589	However	_	_	_	_
7-2	590-591	,	_	_	_	_
7-3	592-594	an	event[25]	new[25]	_	_
7-4	595-600	abuse	event[25]	new[25]	_	_
7-5	601-604	and	_	_	_	_
7-6	605-612	overuse	abstract[26]	new[26]	_	_
7-7	613-615	of	abstract[26]	new[26]	_	_
7-8	616-621	those	abstract[26]|substance[27]	new[26]|giv[27]	coref	8-8[0_27]
7-9	622-633	antibiotics	abstract[26]|substance[27]	new[26]|giv[27]	_	_
7-10	634-636	is	_	_	_	_
7-11	637-640	one	abstract[28]	new[28]	_	_
7-12	641-643	of	abstract[28]	new[28]	_	_
7-13	644-647	the	abstract[28]|abstract[29]	new[28]|new[29]	_	_
7-14	648-655	reasons	abstract[28]|abstract[29]	new[28]|new[29]	_	_
7-15	656-659	for	abstract[28]|abstract[29]	new[28]|new[29]	_	_
7-16	660-663	the	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	coref	15-7[72_30]
7-17	664-671	present	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
7-18	672-678	crisis	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
7-19	679-683	with	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
7-20	684-693	resistant	abstract[28]|abstract[29]|abstract[30]|animal[31]	new[28]|new[29]|new[30]|giv[31]	coref	9-8[0_31]
7-21	694-702	bacteria	abstract[28]|abstract[29]|abstract[30]|animal[31]	new[28]|new[29]|new[30]|giv[31]	_	_
7-22	703-704	.	_	_	_	_

#Text=In the case of viral infections , antibiotics are often prescribed .
8-1	705-707	In	_	_	_	_
8-2	708-711	the	abstract[32]	new[32]	_	_
8-3	712-716	case	abstract[32]	new[32]	_	_
8-4	717-719	of	abstract[32]	new[32]	_	_
8-5	720-725	viral	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
8-6	726-736	infections	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
8-7	737-738	,	_	_	_	_
8-8	739-750	antibiotics	substance	giv	coref	9-10[38_0]
8-9	751-754	are	_	_	_	_
8-10	755-760	often	_	_	_	_
8-11	761-771	prescribed	_	_	_	_
8-12	772-773	.	_	_	_	_

#Text=In the case of existing sensitivities of bacteria towards standard antibiotics , novel reserve antibiotics have been used in clinics .
9-1	774-776	In	_	_	_	_
9-2	777-780	the	abstract[35]	new[35]	_	_
9-3	781-785	case	abstract[35]	new[35]	_	_
9-4	786-788	of	abstract[35]	new[35]	_	_
9-5	789-797	existing	abstract[35]|abstract[36]	new[35]|new[36]	_	_
9-6	798-811	sensitivities	abstract[35]|abstract[36]	new[35]|new[36]	_	_
9-7	812-814	of	abstract[35]|abstract[36]	new[35]|new[36]	_	_
9-8	815-823	bacteria	abstract[35]|abstract[36]|animal	new[35]|new[36]|giv	coref	10-3[41_0]
9-9	824-831	towards	abstract[35]|abstract[36]	new[35]|new[36]	_	_
9-10	832-840	standard	abstract[35]|abstract[36]|substance[38]	new[35]|new[36]|giv[38]	coref	9-13[39_38]
9-11	841-852	antibiotics	abstract[35]|abstract[36]|substance[38]	new[35]|new[36]|giv[38]	_	_
9-12	853-854	,	_	_	_	_
9-13	855-860	novel	substance[39]	giv[39]	coref	10-7[43_39]
9-14	861-868	reserve	substance[39]	giv[39]	_	_
9-15	869-880	antibiotics	substance[39]	giv[39]	_	_
9-16	881-885	have	_	_	_	_
9-17	886-890	been	_	_	_	_
9-18	891-895	used	_	_	_	_
9-19	896-898	in	_	_	_	_
9-20	899-906	clinics	place	new	_	_
9-21	907-908	.	_	_	_	_

#Text=Therefore , bacteria with contact to those antibiotics like Staphylococcus aureus on human surfaces like skin developed early resistances .
10-1	909-918	Therefore	_	_	_	_
10-2	919-920	,	_	_	_	_
10-3	921-929	bacteria	animal[41]	giv[41]	coref	14-3[0_41]
10-4	930-934	with	animal[41]	giv[41]	_	_
10-5	935-942	contact	animal[41]|abstract	giv[41]|new	_	_
10-6	943-945	to	animal[41]	giv[41]	_	_
10-7	946-951	those	animal[41]|substance[43]	giv[41]|giv[43]	coref	11-4[0_43]
10-8	952-963	antibiotics	animal[41]|substance[43]	giv[41]|giv[43]	_	_
10-9	964-968	like	animal[41]|substance[43]	giv[41]|giv[43]	_	_
10-10	969-983	Staphylococcus	animal[41]|substance[43]|abstract	giv[41]|giv[43]|new	coref	32-19
10-11	984-990	aureus	animal[41]|substance[43]	giv[41]|giv[43]	_	_
10-12	991-993	on	animal[41]|substance[43]	giv[41]|giv[43]	_	_
10-13	994-999	human	animal[41]|substance[43]|object[45]	giv[41]|giv[43]|new[45]	_	_
10-14	1000-1008	surfaces	animal[41]|substance[43]|object[45]	giv[41]|giv[43]|new[45]	_	_
10-15	1009-1013	like	animal[41]|substance[43]|object[45]	giv[41]|giv[43]|new[45]	_	_
10-16	1014-1018	skin	animal[41]|substance[43]|object[45]|object	giv[41]|giv[43]|new[45]|new	_	_
10-17	1019-1028	developed	abstract|abstract	new|new	none|none|none|none|none|none|none|none	10-17[0_76]|14-4|10-17[0_79]|14-4|10-17[0_76]|14-4|10-17[0_79]|14-4
10-18	1029-1034	early	abstract[47]	giv[47]	coref	15-1[70_47]
10-19	1035-1046	resistances	abstract[47]	giv[47]	_	_
10-20	1047-1048	.	_	_	_	_

#Text=A misuse of antibiotics is also present in the mast of poultry .
11-1	1049-1050	A	abstract[48]	new[48]	_	_
11-2	1051-1057	misuse	abstract[48]	new[48]	_	_
11-3	1058-1060	of	abstract[48]	new[48]	_	_
11-4	1061-1072	antibiotics	abstract[48]|substance	new[48]|giv	coref	12-1[52_0]
11-5	1073-1075	is	_	_	_	_
11-6	1076-1080	also	_	_	_	_
11-7	1081-1088	present	_	_	_	_
11-8	1089-1091	in	_	_	_	_
11-9	1092-1095	the	object[50]	new[50]	_	_
11-10	1096-1100	mast	object[50]	new[50]	_	_
11-11	1101-1103	of	object[50]	new[50]	_	_
11-12	1104-1111	poultry	object[50]|animal	new[50]|new	_	_
11-13	1112-1113	.	_	_	_	_

#Text=Those antibiotics contaminate the environment by animal excretions .
12-1	1114-1119	Those	substance[52]	giv[52]	coref	15-29[77_52]
12-2	1120-1131	antibiotics	substance[52]	giv[52]	_	_
12-3	1132-1143	contaminate	_	_	_	_
12-4	1144-1147	the	abstract[53]	new[53]	_	_
12-5	1148-1159	environment	abstract[53]	new[53]	_	_
12-6	1160-1162	by	abstract[53]	new[53]	_	_
12-7	1163-1169	animal	abstract[53]|animal|substance[55]	new[53]|new|new[55]	_	_
12-8	1170-1180	excretions	abstract[53]|substance[55]	new[53]|new[55]	_	_
12-9	1181-1182	.	_	_	_	_

#Text=Finally , industrial waste of antibiotic production is pumped into rivers in producing countries like India .
13-1	1183-1190	Finally	_	_	_	_
13-2	1191-1192	,	_	_	_	_
13-3	1193-1203	industrial	abstract[56]	new[56]	_	_
13-4	1204-1209	waste	abstract[56]	new[56]	_	_
13-5	1210-1212	of	abstract[56]	new[56]	_	_
13-6	1213-1223	antibiotic	abstract[56]|substance|abstract[58]	new[56]|new|new[58]	coref|coref	15-9|15-9
13-7	1224-1234	production	abstract[56]|abstract[58]	new[56]|new[58]	_	_
13-8	1235-1237	is	_	_	_	_
13-9	1238-1244	pumped	_	_	_	_
13-10	1245-1249	into	_	_	_	_
13-11	1250-1256	rivers	place	new	_	_
13-12	1257-1259	in	_	_	_	_
13-13	1260-1269	producing	_	_	_	_
13-14	1270-1279	countries	place[60]	giv[60]	coref	17-10[84_60]
13-15	1280-1284	like	place[60]	giv[60]	_	_
13-16	1285-1290	India	place[60]|place	giv[60]|new	_	_
13-17	1291-1292	.	_	_	_	_

#Text=Moreover , bacteria develop resistance mechanisms that allow the spread of resistance genes via plasmids , and also between different species .
14-1	1293-1301	Moreover	_	_	_	_
14-2	1302-1303	,	_	_	_	_
14-3	1304-1312	bacteria	animal	giv	coref	20-16[104_0]
14-4	1313-1320	develop	abstract|abstract	new|new	coref|coref|coref|coref	15-26[76_0]|16-5[79_0]|15-26[76_0]|16-5[79_0]
14-5	1321-1331	resistance	abstract|abstract[64]	new|new[64]	coref|coref	14-12|14-12
14-6	1332-1342	mechanisms	abstract[64]	new[64]	_	_
14-7	1343-1347	that	_	_	_	_
14-8	1348-1353	allow	_	_	_	_
14-9	1354-1357	the	abstract[65]	new[65]	_	_
14-10	1358-1364	spread	abstract[65]	new[65]	_	_
14-11	1365-1367	of	abstract[65]	new[65]	_	_
14-12	1368-1378	resistance	abstract[65]|abstract|abstract[67]	new[65]|giv|new[67]	_	_
14-13	1379-1384	genes	abstract[65]|abstract[67]	new[65]|new[67]	_	_
14-14	1385-1388	via	abstract[65]|abstract[67]	new[65]|new[67]	_	_
14-15	1389-1397	plasmids	abstract[65]|abstract[67]|object	new[65]|new[67]|new	_	_
14-16	1398-1399	,	_	_	_	_
14-17	1400-1403	and	_	_	_	_
14-18	1404-1408	also	_	_	_	_
14-19	1409-1416	between	_	_	_	_
14-20	1417-1426	different	animal[69]	new[69]	_	_
14-21	1427-1434	species	animal[69]	new[69]	_	_
14-22	1435-1436	.	_	_	_	_

#Text=One other problem that contributes to the present antibiotic crisis is the fact that pharmaceutical companies recently announced that they would no longer invest in the development of novel antibiotics .
15-1	1437-1440	One	abstract[70]	giv[70]	coref	15-12[73_70]
15-2	1441-1446	other	abstract[70]	giv[70]	_	_
15-3	1447-1454	problem	abstract[70]	giv[70]	_	_
15-4	1455-1459	that	_	_	_	_
15-5	1460-1471	contributes	_	_	_	_
15-6	1472-1474	to	_	_	_	_
15-7	1475-1478	the	abstract[72]	giv[72]	_	_
15-8	1479-1486	present	abstract[72]	giv[72]	_	_
15-9	1487-1497	antibiotic	substance|abstract[72]	giv|giv[72]	_	_
15-10	1498-1504	crisis	abstract[72]	giv[72]	_	_
15-11	1505-1507	is	_	_	_	_
15-12	1508-1511	the	abstract[73]	giv[73]	_	_
15-13	1512-1516	fact	abstract[73]	giv[73]	_	_
15-14	1517-1521	that	abstract[73]	giv[73]	_	_
15-15	1522-1536	pharmaceutical	abstract[73]|organization[74]	giv[73]|giv[74]	ana	15-20[0_74]
15-16	1537-1546	companies	abstract[73]|organization[74]	giv[73]|giv[74]	_	_
15-17	1547-1555	recently	abstract[73]	giv[73]	_	_
15-18	1556-1565	announced	abstract[73]	giv[73]	_	_
15-19	1566-1570	that	abstract[73]	giv[73]	_	_
15-20	1571-1575	they	abstract[73]|organization	giv[73]|giv	_	_
15-21	1576-1581	would	abstract[73]	giv[73]	_	_
15-22	1582-1584	no	abstract[73]	giv[73]	_	_
15-23	1585-1591	longer	abstract[73]	giv[73]	_	_
15-24	1592-1598	invest	abstract[73]	giv[73]	_	_
15-25	1599-1601	in	_	_	_	_
15-26	1602-1605	the	abstract[76]	new[76]	_	_
15-27	1606-1617	development	abstract[76]	new[76]	_	_
15-28	1618-1620	of	abstract[76]	new[76]	_	_
15-29	1621-1626	novel	abstract[76]|substance[77]	new[76]|giv[77]	coref	16-17[0_77]
15-30	1627-1638	antibiotics	abstract[76]|substance[77]	new[76]|giv[77]	_	_
15-31	1639-1640	.	_	_	_	_

#Text=The financial outcome of the development of life style drugs is much better than that of antibiotics .
16-1	1641-1644	The	abstract[78]	new[78]	_	_
16-2	1645-1654	financial	abstract[78]	new[78]	_	_
16-3	1655-1662	outcome	abstract[78]	new[78]	_	_
16-4	1663-1665	of	abstract[78]	new[78]	_	_
16-5	1666-1669	the	abstract[78]|abstract[79]	new[78]|new[79]	_	_
16-6	1670-1681	development	abstract[78]|abstract[79]	new[78]|new[79]	_	_
16-7	1682-1684	of	abstract[78]|abstract[79]	new[78]|new[79]	_	_
16-8	1685-1689	life	abstract[78]|abstract[79]|substance[80]	new[78]|new[79]|new[80]	coref	29-9[144_80]
16-9	1690-1695	style	abstract[78]|abstract[79]|substance[80]	new[78]|new[79]|new[80]	_	_
16-10	1696-1701	drugs	abstract[78]|abstract[79]|substance[80]	new[78]|new[79]|new[80]	_	_
16-11	1702-1704	is	_	_	_	_
16-12	1705-1709	much	_	_	_	_
16-13	1710-1716	better	_	_	_	_
16-14	1717-1721	than	_	_	_	_
16-15	1722-1726	that	_	_	_	_
16-16	1727-1729	of	_	_	_	_
16-17	1730-1741	antibiotics	substance	giv	coref	17-1
16-18	1742-1743	.	_	_	_	_

#Text=Antibiotics have to be cheap for a use in low-income or developing countries .
17-1	1744-1755	Antibiotics	abstract	giv	coref	18-7[86_0]
17-2	1756-1760	have	_	_	_	_
17-3	1761-1763	to	_	_	_	_
17-4	1764-1766	be	_	_	_	_
17-5	1767-1772	cheap	_	_	_	_
17-6	1773-1776	for	_	_	_	_
17-7	1777-1778	a	abstract[83]	new[83]	coref	25-6[124_83]
17-8	1779-1782	use	abstract[83]	new[83]	_	_
17-9	1783-1785	in	abstract[83]	new[83]	_	_
17-10	1786-1796	low-income	abstract[83]|place[84]	new[83]|giv[84]	_	_
17-11	1797-1799	or	abstract[83]|place[84]	new[83]|giv[84]	_	_
17-12	1800-1810	developing	abstract[83]|place[84]	new[83]|giv[84]	_	_
17-13	1811-1820	countries	abstract[83]|place[84]	new[83]|giv[84]	_	_
17-14	1821-1822	.	_	_	_	_

#Text=Innovative but vague approaches to find novel antibiotics have been an influencing of the bacterial gene expression to modify the bacterial metabolism .
18-1	1823-1833	Innovative	abstract[85]	new[85]	coref	18-11[87_85]
18-2	1834-1837	but	abstract[85]	new[85]	_	_
18-3	1838-1843	vague	abstract[85]	new[85]	_	_
18-4	1844-1854	approaches	abstract[85]	new[85]	_	_
18-5	1855-1857	to	_	_	_	_
18-6	1858-1862	find	_	_	_	_
18-7	1863-1868	novel	substance[86]	giv[86]	coref	21-7[108_86]
18-8	1869-1880	antibiotics	substance[86]	giv[86]	_	_
18-9	1881-1885	have	_	_	_	_
18-10	1886-1890	been	_	_	_	_
18-11	1891-1893	an	abstract[87]	giv[87]	_	_
18-12	1894-1905	influencing	abstract[87]	giv[87]	_	_
18-13	1906-1908	of	abstract[87]	giv[87]	_	_
18-14	1909-1912	the	abstract[87]|abstract[90]	giv[87]|new[90]	coref	20-4[100_90]
18-15	1913-1922	bacterial	abstract[87]|person|abstract[90]	giv[87]|new|new[90]	coref	18-21
18-16	1923-1927	gene	abstract[87]|abstract|abstract[90]	giv[87]|new|new[90]	coref	20-4
18-17	1928-1938	expression	abstract[87]|abstract[90]	giv[87]|new[90]	_	_
18-18	1939-1941	to	_	_	_	_
18-19	1942-1948	modify	_	_	_	_
18-20	1949-1952	the	abstract[92]	new[92]	coref	19-1[93_92]
18-21	1953-1962	bacterial	object|abstract[92]	giv|new[92]	_	_
18-22	1963-1973	metabolism	abstract[92]	new[92]	_	_
18-23	1974-1975	.	_	_	_	_

#Text=Such a modified metabolism might lead to novel metabolic products which have to be identified and tested for their antibacterial properties .
19-1	1976-1980	Such	abstract[93]	giv[93]	_	_
19-2	1981-1982	a	abstract[93]	giv[93]	_	_
19-3	1983-1991	modified	abstract[93]	giv[93]	_	_
19-4	1992-2002	metabolism	abstract[93]	giv[93]	_	_
19-5	2003-2008	might	_	_	_	_
19-6	2009-2013	lead	_	_	_	_
19-7	2014-2016	to	_	_	_	_
19-8	2017-2022	novel	abstract[95]	new[95]	ana	19-19[0_95]
19-9	2023-2032	metabolic	person|abstract[95]	new|new[95]	_	_
19-10	2033-2041	products	abstract[95]	new[95]	_	_
19-11	2042-2047	which	_	_	_	_
19-12	2048-2052	have	_	_	_	_
19-13	2053-2055	to	_	_	_	_
19-14	2056-2058	be	_	_	_	_
19-15	2059-2069	identified	_	_	_	_
19-16	2070-2073	and	_	_	_	_
19-17	2074-2080	tested	_	_	_	_
19-18	2081-2084	for	_	_	_	_
19-19	2085-2090	their	abstract|abstract[97]	giv|new[97]	coref|coref	25-4[123_97]|25-4[123_97]
19-20	2091-2104	antibacterial	abstract[97]	new[97]	_	_
19-21	2105-2115	properties	abstract[97]	new[97]	_	_
19-22	2116-2117	.	_	_	_	_

#Text=Methods to alter gene expression may be varied growth conditions or a microbial co-culturing of various bacteria or of fungi and bacteria .
20-1	2118-2125	Methods	object	new	_	_
20-2	2126-2128	to	_	_	_	_
20-3	2129-2134	alter	_	_	_	_
20-4	2135-2139	gene	abstract|abstract[100]	giv|giv[100]	_	_
20-5	2140-2150	expression	abstract[100]	giv[100]	_	_
20-6	2151-2154	may	_	_	_	_
20-7	2155-2157	be	_	_	_	_
20-8	2158-2164	varied	_	_	_	_
20-9	2165-2171	growth	abstract|abstract[102]	new|new[102]	_	_
20-10	2172-2182	conditions	abstract[102]	new[102]	_	_
20-11	2183-2185	or	_	_	_	_
20-12	2186-2187	a	abstract[103]	new[103]	_	_
20-13	2188-2197	microbial	abstract[103]	new[103]	_	_
20-14	2198-2210	co-culturing	abstract[103]	new[103]	_	_
20-15	2211-2213	of	abstract[103]	new[103]	_	_
20-16	2214-2221	various	abstract[103]|animal[104]	new[103]|giv[104]	coref	32-8[160_104]
20-17	2222-2230	bacteria	abstract[103]|animal[104]	new[103]|giv[104]	_	_
20-18	2231-2233	or	abstract[103]|animal[104]	new[103]|giv[104]	_	_
20-19	2234-2236	of	abstract[103]|animal[104]	new[103]|giv[104]	_	_
20-20	2237-2242	fungi	abstract[103]|animal[104]|animal	new[103]|giv[104]|new	_	_
20-21	2243-2246	and	abstract[103]|animal[104]	new[103]|giv[104]	_	_
20-22	2247-2255	bacteria	abstract[103]|animal[104]	new[103]|giv[104]	_	_
20-23	2256-2257	.	_	_	_	_

#Text=Other sources for the identification of novel antibiotics have been plants , marine invertebrates and insects or amphibia .
21-1	2258-2263	Other	object[106]	giv[106]	coref	21-11[109_106]
21-2	2264-2271	sources	object[106]	giv[106]	_	_
21-3	2272-2275	for	object[106]	giv[106]	_	_
21-4	2276-2279	the	object[106]|abstract[107]	giv[106]|new[107]	_	_
21-5	2280-2294	identification	object[106]|abstract[107]	giv[106]|new[107]	_	_
21-6	2295-2297	of	object[106]|abstract[107]	giv[106]|new[107]	_	_
21-7	2298-2303	novel	object[106]|abstract[107]|substance[108]	giv[106]|new[107]|giv[108]	coref	29-4[143_108]
21-8	2304-2315	antibiotics	object[106]|abstract[107]|substance[108]	giv[106]|new[107]|giv[108]	_	_
21-9	2316-2320	have	_	_	_	_
21-10	2321-2325	been	_	_	_	_
21-11	2326-2332	plants	object[109]	giv[109]	coref	22-5[114_109]
21-12	2333-2334	,	object[109]	giv[109]	_	_
21-13	2335-2341	marine	object[109]|place[110]	giv[109]|new[110]	_	_
21-14	2342-2355	invertebrates	object[109]|place[110]	giv[109]|new[110]	_	_
21-15	2356-2359	and	object[109]	giv[109]	_	_
21-16	2360-2367	insects	object[109]|animal	giv[109]|new	_	_
21-17	2368-2370	or	object[109]	giv[109]	_	_
21-18	2371-2379	amphibia	object[109]|animal	giv[109]|new	_	_
21-19	2380-2381	.	_	_	_	_

#Text=Isolated antimicrobial peptides from such sources have long been favored .
22-1	2382-2390	Isolated	substance[113]	new[113]	coref	25-19[126_113]
22-2	2391-2404	antimicrobial	substance[113]	new[113]	_	_
22-3	2405-2413	peptides	substance[113]	new[113]	_	_
22-4	2414-2418	from	substance[113]	new[113]	_	_
22-5	2419-2423	such	substance[113]|object[114]	new[113]|giv[114]	ana	23-3[0_114]
22-6	2424-2431	sources	substance[113]|object[114]	new[113]|giv[114]	_	_
22-7	2432-2436	have	_	_	_	_
22-8	2437-2441	long	_	_	_	_
22-9	2442-2446	been	_	_	_	_
22-10	2447-2454	favored	_	_	_	_
22-11	2455-2456	.	_	_	_	_

#Text=However , they still hamper with various problems like proteolytic instability , short in vivo half-lives , insufficient solubility and a poor bioavailability .
23-1	2457-2464	However	_	_	_	_
23-2	2465-2466	,	_	_	_	_
23-3	2467-2471	they	object	giv	ana	25-1
23-4	2472-2477	still	_	_	_	_
23-5	2478-2484	hamper	_	_	_	_
23-6	2485-2489	with	_	_	_	_
23-7	2490-2497	various	abstract[116]	new[116]	coref	25-16[0_116]
23-8	2498-2506	problems	abstract[116]	new[116]	_	_
23-9	2507-2511	like	abstract[116]	new[116]	_	_
23-10	2512-2523	proteolytic	abstract[116]|abstract[117]	new[116]|new[117]	_	_
23-11	2524-2535	instability	abstract[116]|abstract[117]	new[116]|new[117]	_	_
23-12	2536-2537	,	abstract[116]	new[116]	_	_
23-13	2538-2543	short	abstract[116]	new[116]	_	_
23-14	2544-2546	in	abstract[116]	new[116]	_	_
23-15	2547-2551	vivo	abstract[116]|abstract[118]	new[116]|new[118]	_	_
23-16	2552-2562	half-lives	abstract[116]|abstract[118]	new[116]|new[118]	_	_
23-17	2563-2564	,	abstract[116]	new[116]	_	_
23-18	2565-2577	insufficient	abstract[116]|abstract[119]	new[116]|new[119]	_	_
23-19	2578-2588	solubility	abstract[116]|abstract[119]	new[116]|new[119]	_	_
23-20	2589-2592	and	abstract[116]	new[116]	_	_
23-21	2593-2594	a	abstract[116]|abstract[120]	new[116]|new[120]	_	_
23-22	2595-2599	poor	abstract[116]|abstract[120]	new[116]|new[120]	_	_
23-23	2600-2615	bioavailability	abstract[116]|abstract[120]	new[116]|new[120]	_	_
23-24	2616-2617	.	_	_	_	_

#Text=Alternative small-molecule antibacterials are rare .
24-1	2618-2629	Alternative	abstract[121]	giv[121]	coref	26-3[127_121]
24-2	2630-2644	small-molecule	abstract[121]	giv[121]	_	_
24-3	2645-2659	antibacterials	abstract[121]	giv[121]	_	_
24-4	2660-2663	are	_	_	_	_
24-5	2664-2668	rare	_	_	_	_
24-6	2669-2670	.	_	_	_	_

#Text=They own promising properties for an oral use , and are not expected to show problems reported for those antimicrobial peptides .
25-1	2671-2675	They	object	giv	_	_
25-2	2676-2679	own	_	_	_	_
25-3	2680-2689	promising	_	_	_	_
25-4	2690-2700	properties	abstract[123]	giv[123]	_	_
25-5	2701-2704	for	abstract[123]	giv[123]	_	_
25-6	2705-2707	an	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
25-7	2708-2712	oral	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
25-8	2713-2716	use	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
25-9	2717-2718	,	_	_	_	_
25-10	2719-2722	and	_	_	_	_
25-11	2723-2726	are	_	_	_	_
25-12	2727-2730	not	_	_	_	_
25-13	2731-2739	expected	_	_	_	_
25-14	2740-2742	to	_	_	_	_
25-15	2743-2747	show	_	_	_	_
25-16	2748-2756	problems	abstract	giv	_	_
25-17	2757-2765	reported	_	_	_	_
25-18	2766-2769	for	_	_	_	_
25-19	2770-2775	those	substance[126]	giv[126]	_	_
25-20	2776-2789	antimicrobial	substance[126]	giv[126]	_	_
25-21	2790-2798	peptides	substance[126]	giv[126]	_	_
25-22	2799-2800	.	_	_	_	_

#Text=Presently , such small-molecule antibacterials that result from synthetic chemistry are unknown to emerge as a novel antibacterial compound class .
26-1	2801-2810	Presently	_	_	_	_
26-2	2811-2812	,	_	_	_	_
26-3	2813-2817	such	abstract[127]	giv[127]	coref	27-10[133_127]
26-4	2818-2832	small-molecule	abstract[127]	giv[127]	_	_
26-5	2833-2847	antibacterials	abstract[127]	giv[127]	_	_
26-6	2848-2852	that	_	_	_	_
26-7	2853-2859	result	abstract	new	coref|none	33-11[170_0]|26-7[0_170]
26-8	2860-2864	from	_	_	_	_
26-9	2865-2874	synthetic	abstract[128]	new[128]	_	_
26-10	2875-2884	chemistry	abstract[128]	new[128]	_	_
26-11	2885-2888	are	_	_	_	_
26-12	2889-2896	unknown	_	_	_	_
26-13	2897-2899	to	_	_	_	_
26-14	2900-2906	emerge	_	_	_	_
26-15	2907-2909	as	_	_	_	_
26-16	2910-2911	a	_	_	_	_
26-17	2912-2917	novel	_	_	_	_
26-18	2918-2931	antibacterial	_	_	_	_
26-19	2932-2940	compound	abstract	new	coref	32-3
26-20	2941-2946	class	_	_	_	_
26-21	2947-2948	.	_	_	_	_

#Text=We gained access to two novel structurally-related classes of small-molecule antibacterials by the reaction of substituted indoles and thiophene dicarbaldehyde .
27-1	2949-2951	We	person	acc	ana	32-1
27-2	2952-2958	gained	_	_	_	_
27-3	2959-2965	access	abstract	new	_	_
27-4	2966-2968	to	_	_	_	_
27-5	2969-2972	two	_	_	_	_
27-6	2973-2978	novel	_	_	_	_
27-7	2979-2999	structurally-related	person[132]	new[132]	coref	32-1[159_132]
27-8	3000-3007	classes	person[132]	new[132]	_	_
27-9	3008-3010	of	person[132]	new[132]	_	_
27-10	3011-3025	small-molecule	person[132]|abstract[133]	new[132]|giv[133]	_	_
27-11	3026-3040	antibacterials	person[132]|abstract[133]	new[132]|giv[133]	_	_
27-12	3041-3043	by	_	_	_	_
27-13	3044-3047	the	event[134]	new[134]	_	_
27-14	3048-3056	reaction	event[134]	new[134]	_	_
27-15	3057-3059	of	event[134]	new[134]	_	_
27-16	3060-3071	substituted	event[134]|substance[135]|abstract[136]	new[134]|new[135]|new[136]	coref|coref|coref|coref	28-10[139_135]|28-10[140_136]|28-10[139_135]|28-10[140_136]
27-17	3072-3079	indoles	event[134]|substance[135]|abstract[136]	new[134]|new[135]|new[136]	_	_
27-18	3080-3083	and	event[134]|abstract[136]	new[134]|new[136]	_	_
27-19	3084-3093	thiophene	event[134]|abstract[136]|organization	new[134]|new[136]|new	_	_
27-20	3094-3108	dicarbaldehyde	event[134]	new[134]	_	_
27-21	3109-3110	.	_	_	_	_

#Text=Therefore , various composed hybrid molecules were yielded from those indoles and benzothiophene .
28-1	3111-3120	Therefore	_	_	_	_
28-2	3121-3122	,	_	_	_	_
28-3	3123-3130	various	object[138]	new[138]	coref	29-1[142_138]
28-4	3131-3139	composed	object[138]	new[138]	_	_
28-5	3140-3146	hybrid	object[138]	new[138]	_	_
28-6	3147-3156	molecules	object[138]	new[138]	_	_
28-7	3157-3161	were	_	_	_	_
28-8	3162-3169	yielded	_	_	_	_
28-9	3170-3174	from	_	_	_	_
28-10	3175-3180	those	substance[139]|abstract[140]	giv[139]|giv[140]	ana|ana	30-1[0_140]|30-1[0_140]
28-11	3181-3188	indoles	substance[139]|abstract[140]	giv[139]|giv[140]	_	_
28-12	3189-3192	and	abstract[140]	giv[140]	_	_
28-13	3193-3207	benzothiophene	abstract[140]|substance	giv[140]|new	ana	30-4[146_0]
28-14	3208-3209	.	_	_	_	_

#Text=Hybrid molecules of antimicrobial active antibiotics , or antifungal drugs have recently been reviewed .
29-1	3210-3216	Hybrid	object[142]	giv[142]	_	_
29-2	3217-3226	molecules	object[142]	giv[142]	_	_
29-3	3227-3229	of	object[142]	giv[142]	_	_
29-4	3230-3243	antimicrobial	object[142]|substance[143]	giv[142]|giv[143]	coref	10-17[0_143]
29-5	3244-3250	active	object[142]|substance[143]	giv[142]|giv[143]	_	_
29-6	3251-3262	antibiotics	object[142]|substance[143]	giv[142]|giv[143]	_	_
29-7	3263-3264	,	object[142]	giv[142]	_	_
29-8	3265-3267	or	object[142]	giv[142]	_	_
29-9	3268-3278	antifungal	object[142]|substance[144]	giv[142]|giv[144]	_	_
29-10	3279-3284	drugs	object[142]|substance[144]	giv[142]|giv[144]	_	_
29-11	3285-3289	have	_	_	_	_
29-12	3290-3298	recently	_	_	_	_
29-13	3299-3303	been	_	_	_	_
29-14	3304-3312	reviewed	_	_	_	_
29-15	3313-3314	.	_	_	_	_

#Text=They mostly consist either of two different antibiotics or antifungals that are connected by a linker like a simple carbon chain .
30-1	3315-3319	They	abstract	giv	_	_
30-2	3320-3326	mostly	_	_	_	_
30-3	3327-3334	consist	_	_	_	_
30-4	3335-3341	either	substance[146]	giv[146]	_	_
30-5	3342-3344	of	substance[146]	giv[146]	_	_
30-6	3345-3348	two	substance[146]|substance[147]	giv[146]|giv[147]	_	_
30-7	3349-3358	different	substance[146]|substance[147]	giv[146]|giv[147]	_	_
30-8	3359-3370	antibiotics	substance[146]|substance[147]	giv[146]|giv[147]	_	_
30-9	3371-3373	or	substance[146]|substance[147]	giv[146]|giv[147]	_	_
30-10	3374-3385	antifungals	substance[146]|substance[147]|substance	giv[146]|giv[147]|new	_	_
30-11	3386-3390	that	_	_	_	_
30-12	3391-3394	are	_	_	_	_
30-13	3395-3404	connected	_	_	_	_
30-14	3405-3407	by	_	_	_	_
30-15	3408-3409	a	object[149]	new[149]	_	_
30-16	3410-3416	linker	object[149]	new[149]	_	_
30-17	3417-3421	like	object[149]	new[149]	_	_
30-18	3422-3423	a	object[149]|object[151]	new[149]|new[151]	_	_
30-19	3424-3430	simple	object[149]|object[151]	new[149]|new[151]	_	_
30-20	3431-3437	carbon	object[149]|substance|object[151]	new[149]|new|new[151]	_	_
30-21	3438-3443	chain	object[149]|object[151]	new[149]|new[151]	_	_
30-22	3444-3445	.	_	_	_	_

#Text=So fluoroquinolone-oxazolidinone hybrids reached clinical trials and novel 1 , 2 , 3-triazole antifungal hybrids with 8-aminoquinoline or dioxolane have recently been reported .
31-1	3446-3448	So	_	_	_	_
31-2	3449-3478	fluoroquinolone-oxazolidinone	object[152]	new[152]	coref	31-13[154_152]
31-3	3479-3486	hybrids	object[152]	new[152]	_	_
31-4	3487-3494	reached	_	_	_	_
31-5	3495-3503	clinical	abstract[153]	new[153]	_	_
31-6	3504-3510	trials	abstract[153]	new[153]	_	_
31-7	3511-3514	and	_	_	_	_
31-8	3515-3520	novel	_	_	_	_
31-9	3521-3522	1	_	_	_	_
31-10	3523-3524	,	_	_	_	_
31-11	3525-3526	2	_	_	_	_
31-12	3527-3528	,	_	_	_	_
31-13	3529-3539	3-triazole	object[154]	giv[154]	_	_
31-14	3540-3550	antifungal	object[154]	giv[154]	_	_
31-15	3551-3558	hybrids	object[154]	giv[154]	_	_
31-16	3559-3563	with	object[154]	giv[154]	_	_
31-17	3564-3580	8-aminoquinoline	object[154]|abstract	giv[154]|new	_	_
31-18	3581-3583	or	object[154]	giv[154]	_	_
31-19	3584-3593	dioxolane	object[154]|substance	giv[154]|new	_	_
31-20	3594-3598	have	_	_	_	_
31-21	3599-3607	recently	_	_	_	_
31-22	3608-3612	been	_	_	_	_
31-23	3613-3621	reported	_	_	_	_
31-24	3622-3623	.	_	_	_	_

#Text=Our novel compound classes were tested against prominent Gram-positive bacteria that are associated with severe hospital infections by Staphylococcus and Enterococcus strains .
32-1	3624-3627	Our	person|person[159]	giv|giv[159]	ana|ana	33-1|33-1
32-2	3628-3633	novel	person[159]	giv[159]	_	_
32-3	3634-3642	compound	abstract|person[159]	giv|giv[159]	_	_
32-4	3643-3650	classes	person[159]	giv[159]	_	_
32-5	3651-3655	were	_	_	_	_
32-6	3656-3662	tested	_	_	_	_
32-7	3663-3670	against	_	_	_	_
32-8	3671-3680	prominent	animal[160]	giv[160]	_	_
32-9	3681-3694	Gram-positive	animal[160]	giv[160]	_	_
32-10	3695-3703	bacteria	animal[160]	giv[160]	_	_
32-11	3704-3708	that	_	_	_	_
32-12	3709-3712	are	_	_	_	_
32-13	3713-3723	associated	_	_	_	_
32-14	3724-3728	with	_	_	_	_
32-15	3729-3735	severe	abstract[162]	new[162]	_	_
32-16	3736-3744	hospital	place|abstract[162]	new|new[162]	_	_
32-17	3745-3755	infections	abstract[162]	new[162]	_	_
32-18	3756-3758	by	_	_	_	_
32-19	3759-3773	Staphylococcus	substance|abstract[165]	giv|new[165]	_	_
32-20	3774-3777	and	abstract[165]	new[165]	_	_
32-21	3778-3790	Enterococcus	abstract|abstract[165]	new|new[165]	_	_
32-22	3791-3798	strains	abstract[165]	new[165]	_	_
32-23	3799-3800	.	_	_	_	_

#Text=We identified first lead compounds with promising activities and confirmed the in vitro results first in the in vivo studies for selected derivatives .
33-1	3801-3803	We	person	giv	_	_
33-2	3804-3814	identified	_	_	_	_
33-3	3815-3820	first	_	_	_	_
33-4	3821-3825	lead	person|substance[168]	new|new[168]	_	_
33-5	3826-3835	compounds	substance[168]	new[168]	_	_
33-6	3836-3840	with	substance[168]	new[168]	_	_
33-7	3841-3850	promising	substance[168]|abstract[169]	new[168]|new[169]	_	_
33-8	3851-3861	activities	substance[168]|abstract[169]	new[168]|new[169]	_	_
33-9	3862-3865	and	_	_	_	_
33-10	3866-3875	confirmed	_	_	_	_
33-11	3876-3879	the	abstract[170]	new[170]	_	_
33-12	3880-3882	in	abstract[170]	new[170]	_	_
33-13	3883-3888	vitro	abstract[170]	new[170]	_	_
33-14	3889-3896	results	abstract[170]	new[170]	_	_
33-15	3897-3902	first	_	_	_	_
33-16	3903-3905	in	_	_	_	_
33-17	3906-3909	the	event[171]	new[171]	_	_
33-18	3910-3912	in	event[171]	new[171]	_	_
33-19	3913-3917	vivo	event[171]	new[171]	_	_
33-20	3918-3925	studies	event[171]	new[171]	_	_
33-21	3926-3929	for	event[171]	new[171]	_	_
33-22	3930-3938	selected	event[171]|substance[172]	new[171]|new[172]	_	_
33-23	3939-3950	derivatives	event[171]|substance[172]	new[171]|new[172]	_	_
33-24	3951-3952	.	_	_	_	_
